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MarcW. Gibson¤a, Simon Dewar, Han B. Ong¤b, Natasha Sienkiewicz, Alan H. Fairlamb*
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Bifunctional dihydrofolate reductase–thymidylate synthase (DHFR-TS) is a chemically and
genetically validated target in African trypanosomes, causative agents of sleeping sickness
in humans and nagana in cattle. Here we report the kinetic properties and sensitivity of
recombinant enzyme to a range of lipophilic and classical antifolate drugs. The purified
recombinant enzyme, expressed as a fusion protein with elongation factor Ts (Tsf) in ThyA-
Escherichia coli, retains DHFR activity, but lacks any TS activity. TS activity was found to be
extremely unstable (half-life of 28 s) following desalting of clarified bacterial lysates to
remove small molecules. Stability could be improved 700-fold by inclusion of dUMP, but not
by other pyrimidine or purine (deoxy)-nucleosides or nucleotides. Inclusion of dUMP during
purification proved insufficient to prevent inactivation during the purification procedure.
Methotrexate and trimetrexate were the most potent inhibitors of DHFR (Ki 0.1 and 0.6 nM,
respectively) and FdUMP and nolatrexed of TS (Ki 14 and 39 nM, respectively). All inhibitors
showed a marked drop-off in potency of 100- to 1,000-fold against trypanosomes grown in
low folate medium lacking thymidine. The most potent inhibitors possessed a terminal gluta-
mate moiety suggesting that transport or subsequent retention by polyglutamylation was
important for biological activity. Supplementation of culture medium with folate markedly
antagonised the potency of these folate-like inhibitors, as did thymidine in the case of the
TS inhibitors raltitrexed and pemetrexed.
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Author Summary
There are few validated and fully characterised targets suitable for drug discovery against
African trypanosomes, causative agents of sleeping sickness in humans and nagana in cat-
tle. Here we report the biochemical properties of the bifunctional enzyme, dihydrofolate
reductase–thymidylate synthase (DHFR-TS), and its susceptibility to a range of classical
inhibitors normally used in the treatment of cancer, bacterial or protozoal infections.
Some of these drugs are extremely potent against the isolated enzyme, but much less so
against the intact trypanosome. We have found that modulating certain medium compo-
nents can affect drug sensitivity, presumably by either competition for uptake and compe-
tition for the active site of DHFR-TS. In the case of one human TS inhibitor (raltitrexed)
the inhibitor is more potent against the intact parasite. We propose that addition of extra
glutamic acid residues not only improves retention in the cell, but also increases potency
against TS, as it does in human cells.
Introduction
Human African trypanosomiasis (HAT) is an infectious disease caused by two distinct subspe-
cies of the protozoan parasite Trypanosoma brucei (T. b. gambiense and T. b. rhodesiense).
Existing therapies for this otherwise fatal disease are limited due to toxicity, difficulty in admin-
istration, emerging drug resistance and cost. As such, new safe and affordable drugs are
required for the continued treatment and control of HAT. Enzymes of essential metabolic
pathways in T. brucei, such as N-myristoyltransferase [1] and trypanothione synthetase [2,3],
are of continuing interest as novel targets for the development of new treatments, while a num-
ber of other putative drug targets remain to be fully exploited. One example is the bifunctional
folate and pyrimidine-metabolising enzyme dihydrofolate reductase-thymidylate synthase
(DHFR-TS). In T. brucei, this enzyme is expressed from a single gene as a homodimer compris-
ing of an N-terminal DHFR domain fused via a linker peptide to a TS domain at the C-termi-
nus. In contrast, DHFR and TS are expressed separately from independent genes in many
other organisms, including humans. In trypanosomatids, DHFR catalyses reduction of dihy-
drofolate (DHF) by NADPH to form tetrahydrofolate (THF) which is then converted to N5,
N10-methylenetetrahydrofolate (CH2THF), either via the glycine cleavage system or by serine
hydroxymethyltransferase (the latter is absent in T. brucei). CH2THF serves as carbon donor
for the reductive methylation of deoxyuridine monophosphate (dUMP) to form thymidylate
(dTMP) catalysed by TS [4]. dTMP is ultimately phosphorylated to thymidine triphosphate
(dTTP) and used for DNA synthesis and DNA repair (Fig 1). T. brucei can also salvage extra-
cellular thymidine by-passing de novo synthesis. Unlike apicomplexan parasites, trypanosomes
lack the ability to synthesise folate and take up serum folate or 5-methyltetrahydrofolate via
putative folate transporters. Concentration and retention of folate may involve polyglutamyla-
tion as in other organisms, although this has not been established for T. brucei.
DHFR-TS is essential for cell survival and has been previously validated (both genetically
and chemically) as a potential drug target in T. brucei [6]. Despite significant evolutionary sep-
aration between protozoa and mammals, T. brucei TS is highly similar to its human homologue
with 60% identity and an active site that is identical at the amino acid level. T. brucei DHFR is
less well-conserved with only 28% identity with the human enzyme. Indeed, the DHFR domain
from several protozoan species has been successfully exploited as a drug target, most notably in
the treatment of malaria by the DHF-competitive inhibitors pyrimethamine and cycloguanil
[7] which, based on their structural similarity to natural folates, belong to the class of
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antimetabolites known collectively as the antifolates. These compounds deplete the cellular
THF pool, which in turn inhibits dTMP and DNA synthesis resulting in what is known as ‘thy-
mineless-death’ [8,9]. To date, antifolates have not been evaluated as chemotherapeutics in ani-
mal models of HAT. Newer antifolates such as nolatrexed [10], pemetrexed [11] and
raltitrexed [12] have been designed to directly inhibit TS and have proven useful as cancer che-
motherapies; however, these compounds only possess low potency against trypanosomes in
thymidine-rich medium [6]. In contrast to Leishmania DHFR-TS, the TS domain of
TbDHFR-TS has long proven to be an elusive drug target due to an inability to express the
enzyme in an active recombinant form [13], which precluded a thorough characterisation of its
activity and its sensitivity to inhibitors. Here we describe the first successful recombinant pro-
duction of bifunctional T. brucei DHFR-TS (TbDHFR-TS) in the form of a fusion protein
incorporating Escherichia coli elongation factor Ts (Tsf) [14]. We also biochemically character-
ise the two activities of TbDHFR-TS and describe their sensitivities to a variety of known inhib-
itors, along with corresponding in vivo potencies in wild type T. brucei. We show that the
challenges faced in recombinant TbDHFR-TS production are the result of instability in the TS
Fig 1. Folate metabolism and the thymidylate cycle in T. brucei. Enzymes catalysing key metabolic steps are: 1, thymidylate
synthase (EC 2.1.1.45); 2, dihydrofolate reductase (EC 1.5.1.3); 3, glycine cleavage system (EC 1.4.4.2, 1.8.1.4 and 2.1.2.10; 4 pteridine
reductase (EC 1.5.1.33); 5, methionine synthase (EC 2.1.1.13); 6, thymidine kinase (EC 2.7.1.21). These parasites are folate and purine
auxotrophs and obtain these essential metabolites from the extracellular medium. Although they have retained the capacity for de novo
pyrimidine biosynthesis, they can also salvage extracellular thymidine, thereby by-passing inhibition of the thymidylate cycle. As reported
in this manuscript, folic acid is not a substrate for DHFR, but TbPTR1 is reported to display low activity in reducing folate and
dihydrofolate (DHF) [5].
doi:10.1371/journal.pntd.0004714.g001
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domain, rather than proteolysis, as was previously hypothesised [13], and how a combination
of TS-stabilising small molecules and macromolecules can overcome this limitation, suggesting
that an as-of-yet unidentified TS-stabilising factor could be present in T. brucei and possibly
other species as well. Through comparisons of in vitro and in vivo potencies of known DHFR
and TS inhibitors, we also show that additional targets for these compounds remain to be iden-
tified in T. brucei.
Methods
Organisms and reagents
T. brucei strain 427 was the original source for DNA used in recombinant enzyme production.
All reagents were of the highest quality available from Sigma, unless otherwise specified.
Recombinant protein expression employed a previously described TS-deficient (thyA-) E. coli
strain [6], derived from Invitrogen BL21 Star (DE3). Restriction enzymes and Pfu DNA poly-
merase were from Promega. Site-directed mutagenesis was performed using the QuikChange
Site-Directed Mutagenesis Kit, Stratagene. DHFR and TS inhibitors were sourced as follows:
methotrexate, 5-fluorouracil, 5-fluorodeoxyuridine monophosphate (FdUMP), trimethoprim
and pyrimethamine from Sigma Aldrich; nolatrexed, pemetrexed and raltitrexed from Sequoia
Research Products; and trimetrexate from Tocris Bioscience.
Cloning of expression constructs
The solubility enhancing factor Tsf [14] was engineered into a modified pET15b expression
vector containing a Tobacco Etch Virus (TEV) protease recognition sequence in place of a
thrombin recognition sequence (pET15b_TEV) [15]. The Tsf open reading frame was ampli-
fied by PCR from the genomic DNA (gDNA) of E. coli strain K12 using specific oligonucleo-
tides (EcTsf_s and EcTsf_as, S1 Table) and pfu polymerase. The stop codon in the Tsf gene was
replaced with a threonine-encoding ACC codon and the PCR product (866 bp) was cloned
into the NcoI restriction site on the pET15b_TEV vector resulting in an expression cassette
containing Tsf-(His)6-TEV. The open reading frame of DHFR-TS was amplified by PCR from
T. brucei gDNA using specific oligonucleotides (TbDHFR-TS_s and TbDHFR-TS_as, S1 Table).
To express TbDHFR-TS on its own or in frame with EcTsf, the PCR product (1597 bp) was
cloned into the BamHI restriction site in either pET15b_TEV or pET15b_Tsf-TEV to generate
the pET15b_TEV-DHFR-TS and pET15b_Tsf-TEV-DHFR-TS expression constructs, respec-
tively. To create a pET15b_Tsf-TEV-TS fusion construct without the DHFR domain, TS (884
bp) was PCR-amplified using oligonucleotides TbTS_s and TbTS_as (S1 Table) from
pET15b_Tsf-TEV-DHFR-TS and cloned into the BamHI restriction site on pET15b_Ts-TEV.
To express DHFR without the TS domain, a stop codon (TAA), immediately after the last
amino acid (Arg 239) of DHFR, was introduced into the above DHFR-TS expression con-
structs (using oligonucleotides TbDHFR_mut_s and TbDHFR_mut_as, S1 Table) by site-
directed mutagenesis (Stratagene), as per manufacturer’s instruction. The accuracy of all con-
structs was verified by DNA sequencing (http://www.dnaseq.co.uk).
Recombinant expression and purification of TbDHFR-TS
Expression constructs carrying a TS domain from T. brucei, Leishmania major and human TS
(pET15b_Tsf-TEV-TbTS, pET15b_Tsf-TEV-TbDHFR-TS, pET15b_LmDHFR-TS and
pET17b_hTS, respectively) were expressed in a TS-deficient E. coli strain (thyA-), while TbDHFR
without TS (pET15b_TEV-DHFR) was expressed in the parental thyA+ strain. Transformants
were selected on LB agar plates containing carbenicillin (50 μg ml-1). Plates were initially
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incubated at 37°C for 18 h and those not displaying colonies were incubated at room temperature
for a further 3–6 days until colonies appeared. Single colonies were used to set up starter cultures
to inoculate 1 litre of auto-induction media [16] containing 50 μg ml-1 carbenicillin. Cultures
were incubated at room temperature with shaking at 200 r.p.m for 72 h and aliquots of 50 ml
harvested by centrifugation (2,000 g, 10 min, 4°C). Cell pellets were stored at -80°C before use.
Pellets were resuspended in lysis buffer (100 mMHEPES, 100 mMNaCl, 1 mM EDTA, 1 mM
DTT, pH 7.0), lysed by sonication (3 × 30 s, 10 micron amplitude), clarified by centrifugation
(20,000 g, 5 min, 4°C) and supernatants were analysed for DHFR or TS activity.
To purify the recombinant proteins, cultures (1 litre) were harvested by centrifugation
(2,800 g, 30 min, 4°C), resuspended in lysis buffer containing cOmplete Protease Inhibitor
Cocktail (Roche) and lysed using a cell disruptor (Constant Systems) at 30,000 psi. Lysates
were clarified by centrifugation (50,000 g, 30 min, 4°C) and recombinant Tsf-TbDHFR-TS
purified using methotrexate affinity chromatography, as previously described [13]. To cleave
the Tsf tag, TEV protease was used in a 5:1 (mass to mass) ratio, estimated from DHFR specific
activity, at 4°C for up to three days, either in assay buffer following purification or prior to
purification in E. coli lysate treated with up to 40% glycerol. A methotrexate agarose column
(5 ml) was loaded by recirculation, monitoring DHFR activity until the column was saturated,
and then washed exhaustively with buffers consisting of 50 mMHEPES, 1 M KCl, pH 7, 10%
glycerol, followed by 0.5 M KCl, until no further change in absorbance at 280 nM could be
detected. Protein was eluted with one column volume of 50 mMHEPES, 0.5 M KCl, pH 8, 10%
glycerol with 5 mM DHF. Up to 1 mM dUMP was added to buffers and the column operating
temperature reduced to 4°C in an effort to preserve recombinant TS activity. The relative
molecular mass of the cleaved recombinant enzyme was determined by size exclusion chroma-
tography on a Superdex 200 column using Bio-Rad gel filtration standards.
Ethics
All animal experiments were approved by the Ethical Review Committee at the University of
Dundee and performed under the Animals (Scientific Procedures) Act 1986 (UK Home Office
Project Licence PPL 60/4039) in accordance with the European Communities Council Direc-
tive (86/609/EEC).
Native T. brucei lysate preparation
T. brucei trypomastigotes were purified from blood of infected Wistar rats by anion exchange
chromatography [17]. Parasites were resuspended (2.5 x 109 cells ml-1) in lysis buffer plus
cOmplete Protease Inhibitor Cocktail (see above) and biologically inactivated by three rapid
freeze-thaw cycles before lysis using a one-shot cell disruptor (Constant Systems) at 30,000 psi.
Aliquots (500 μl) were stored at -80°C and clarified by centrifugation (20,000 g, 20 min, 4°C)
before use.
Kinetic analysis of DHFR and TS activities
DHFR activity was determined spectrophotometrically at 340 nm [18]. DHFR (5 nM) was pre-
incubated with 100 μMNADPH (Medford) in assay buffer (50 mMHEPES, pH 7.4, containing
100 mM KCl) for 1 min at 25°C (1 ml final assay volume), before the addition of 100 μMDHF
(Sigma Aldrich). Initial rates were calculated from the combined molar extinction coefficient
for NADPH oxidation and DHF reduction (ε = 12,300 M-1 cm-1). The Km
app values for DHFR
substrates were determined by varying the concentration of one substrate in the presence of a
fixed saturating concentration of the other. IC50 values were determined using 8-point dou-
bling dilutions of inhibitor under the above standard assay conditions.
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The initial characterisation of TS was also carried out using a spectrophotometric assay
[19,20]. Owing to the pronounced instability of the recombinant protein, clarified ThyA- E. coli
lysates were used for characterisation, where the concentration of TS was calculated based on
DHFR activity. To determine the Km
app for dUMP, TS (200 nM) was pre-incubated in DHFR-
assay buffer containing varying amounts of dUMP (1.56–100 μM) in 1 ml assay volumes. Enzy-
matic reactions were initiated by the addition of CH2THF (200 μM, Shircks Laboratories) and
initial rates of CH2THF oxidation to DHF monitored by the increase in absorbance at 340 nm
(ε = 6,200 M-1 cm-1). This method is not suitable for determination of the Km
app for CH2THF
and a radiometric method was used instead [21]. This method measures the release of tritiated
water from 5-[3H]-dUMP (American Radiochemicals, 14.3 Ci mmol-1). Assays (40 μl final vol-
ume) contained 200 nM TS and varying amounts of CH2THF (37.5 μM– 4.8 mM) in DHFR-
assay buffer. Reactions were initiated by adding 200 μM [3H]-dUMP (5.55 × 105 dpm nmol-1)
and stopped after 10 min by the addition of 20 μl trichloroacetic acid. Residual 5-[3H]-dUMP
was removed by the addition of 200 μl of 10% (w/v) activated charcoal (Sigma). Aliquots
(100 μl) of the supernatants were added to 2 ml of scintillation fluid (Pico-Fluor 40™, Packard
Bioscience) and radioactivity determined using a Beckmann LS 6500 Scintillation Counter. To
determine TS activity in clarified T. brucei lysates the incubation time was increased to 30 min
and the assay volume was increased to ~200 μl. To assay overexpressed recombinant activity
under comparable linear conditions, working stocks of bacterial lysates were prepared by dilut-
ing 20- to 40-fold with 200 μM dUMP, unless otherwise noted. For stability experiments all
lysates were desalted using 0.5 ml Zeba Spin Desalting Columns (7K MWCO). Protein concen-
trations were determined using the BioRad protein assay based on the method of Bradford
[22]. Inhibitors (8-point doubling dilutions) were assayed using the radiometric method in the
presence of 100 μMCH2THF, 200 μM dUMP and 200 nM Tsf-TbDHFR-TS.
Results were analysed by non-linear regression using GraFit v 5.0.13 (Erithacus Software).
Km
app values were determined using the Michaelis-Menten equation. IC50 values were deter-
mined using eq 1 and Ki values calculated using the Cheng-Prusoff eq 2 [23]. For tight binding
inhibitors, where the Hill slope of the IC50 equation was> 1, the modified Morrison eq 3
[24,25] was used to calculate Ki







(where y is the % activity remaining, x the inhibitor concentration and s the slope factor)
Equation 2. Cheng-Prusoff equation





(where Km is the Michaelis-Menten constant, S is the substrate concentration and Ki
app is the
apparent Ki, expressed here as IC50, see eq 1)
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(where [E]T is the total enzyme concentration and [I]T the total inhibitor concentration).
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Effects of DHFR and TS inhibitors on growth of wild type T. brucei
Wild type (WT) T. brucei bloodstream-form ‘single marker’ S427 were cultured in HMI9T
medium [26] supplemented with 2.5 μg ml-1 G418 to maintain expression of T7 RNA polymer-
ase and the tetracycline repressor protein [27]. HMI9T medium (standard media for T. brucei
cell culture) contains high concentrations of folate (~9 μM) and thymidine (~160 μM) princi-
pally from IMDM and 10% Serum Plus components [6]. A medium based on HMI9T, only
lacking Serum Plus, folate and thymidine was prepared in-house, named trypanosome base
media (TBM; the residual folate is provided by the serum component). A comparison of these
media is described in S2 Table. WT T. brucei cells grow normally in TBM and the rate of
growth is similar to HMI9T in TBM with no supplementation, supplementation with 9 μM
folate, 160 μM thymidine or supplementation with both folate and thymidine (7–8 h doubling
time).
EC50 of antifolates against T. brucei were determined in 96-well microtitre plates. Serial dou-
bling dilutions of antifolate drugs (10–50 mM stocks prepared in DMSO) were prepared in
100 μl of the appropriate medium and trypanosomes (resuspended in the same medium)
added in 100 μl to give a final concentration of 2.5 × 103 cells ml-1. All wells, including controls,
contained a final volume of 0.5% DMSO. Cultures were incubated for 72 h at 37°C / 5% CO2
before cell density was determined using a resazurin-based assay [28]. EC50 values were calcu-
lated using GraFit v 5.0.13 (Erithacus Software) with a 3-parameter non-linear regression from
triplicate readings. Antifolates were tested against parasites cultured in TBM; this allowed for
the addition of thymidine (160 μM) and folate (9 μM) respectively.
Results
Identification of TS-active recombinant TbDHFR-TS
Initial attempts to express recombinant His6-tagged TbDHFR-TS resulted in a low yield of sol-
uble, enzymatically active protein, as previously reported (Table 1) [13]. Although DHFR activ-
ity in clarified E. coli lysates was ~100-fold above background (determined by
spectrophotometric assay), the equivalent assay was insufficiently sensitive to detect any TS
activity. The functionality of TS could only be confirmed by complementation studies using
TS-deficient (thyA-) E. coli strain (S1 Fig). ThyA- cells were unable to grow in the absence of
thymidine supplementation and growth, albeit very slow, was restored in cells transformed
with the pET15b_TbDHFR-TS plasmid with bacterial colonies appearing after 3–6 days incu-
bation. In stark contrast, numerous colonies were formed within 18 h for the positive controls
Table 1. Screening for recombinant T. bruceiDHFR and TS activities as expressed in E. coli.
Construct N-terminal tag E. coli strain Speciﬁc activity, mU mg-1 Ratio DHFR:TS
DHFR TS
Tsf blank vector N/A thyA- a 2.1 ± 0.2 Not detected —
Tsf blank vector N/A thyA+ 3.6 ± 0.2 Not detected b —
TbDHFR His6 thyA
+ 2000 ± 76 Not detected b —
TbDHFR-TS His6 thyA
- 210 ± 14 Not detected —
Tsf-TbDHFR-TS Tsf thyA- 1200 ± 7 8.8 ± 0.1 137:1
Enzyme activity was determined in clariﬁed lysates using the spectrophotometric assays described in the methods. Values are the means and standard
deviations of triplicate assays from a single experiment.
a) Grown in presence of 50 μg ml-1 thymine to compensate for lack of endogenous TS
b) The spectrophotometric assay is insufﬁciently sensitive to detect endogenous TS activity in the thyA+ E. coli host
doi:10.1371/journal.pntd.0004714.t001
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of thyA+ E. coli and thyA- cells complemented with L.major DHFR-TS (S1 Fig). Re-plating of
TbDHFR-TS-complemented cultures resulted in comparable numbers of colonies as seen with
positive controls; however, slow growth persisted. These results, together with the undetectable
activity of TS in lysates, suggest that the TS domain of TbDHFR-TS could be highly unstable.
SDS-PAGE of E. coli lysates also revealed that the majority of TbDHFR-TS was present in the
insoluble pellet of clarified lysates, indicating formation of inclusion bodies.
To determine whether the DHFR or TS domain was responsible for the poor solubility,
constructs separating the two domains were generated, based upon previously reported
boundaries [13]. Expression of the domain-specific constructs resulted in a ~10-fold increased
soluble DHFR expression (Table 1), whereas the independent TS domain failed to comple-
ment thyA- E. coli (S1 Fig).
Attempts to improve the solubility of TS-active TbDHFR-TS using common fusion part-
ners, such as NusA and thioredoxin, were unsuccessful. As an alternative approach, E. coli
elongation factor Ts (Tsf) was examined as a solubility-enhancer [14]. Tsf was engineered
upstream in frame with the His6-TEV site within the pET15b expression vector, to generate a
Tsf expression construct (pET15b_Tsf-His-TEV). This was used as an expression cassette for
the bifunctional DHFR-TS and the individual domains (Tsf-TbDHFR-TS, Tsf-TbTS, Tsf-
TbDHFR).
Functional TS activity of Tsf-TbDHFR-TS was confirmed by its ability to complement
thyA- E. coli cells, whereas Tsf-TbTS did not (S1 Fig). These results indicate that the DHFR
domain provides a structural contribution for TS to be active, which is consistent with previous
findings for Trypanosoma cruzi DHFR-TS [29] and Plasmodium falciparum DHFR-TS [30],
suggesting TS is only functional when in complex with DHFR.
Stabilisation of recombinant T. brucei TS
DHFR activity in lysates of E. coli expressing Tsf-TbDHFR-TS was ~6-fold more active than
those expressing His6-TbDHFR-TS (Table 1). In addition, TS activity which had proved elusive
in the His6-protein could now be detected. Crucially, the addition of dUMP to assay buffer
prior to addition of the enzyme appeared to enhance TS activity. The possible role of dUMP in
the stabilisation of TS was therefore further investigated. TS activity in clarified bacterial lysates
was stable for up to 72 h at 4°C, whereas less than 5% TS activity was retained if small mole-
cules and metabolites (<1,000 Da) were removed using a desalting spin column. The addition
of 200 μM dUMP immediately following desalting preserved the activity of TS, consistent with
several other studies reporting substrate-mediated TS stabilisation by dUMP in other organ-
isms [31–34]. In some cases dUMP is reported to have a synergistic action with CH2THF; how-
ever, in the case of TbDHFR-TS, there was no stabilisation observed with CH2THF, possibly
due to the low affinity for this substrate (see below). Other pyrimidine nucleotides, including
the uracil-containing ribonucleotides and deoxyribonucleotides, and the thymidine-containing
deoxyribonucleotides, were also unable to stabilise TS. Furthermore, common stabilisers such
as 10% glycerol, 1% BSA and 1 mM EDTA were ineffective in preserving TS activity. To deter-
mine if the oxidation of the TS catalytic cysteine could be a reason for its inactivation, 2-mer-
captoethanol (10 mM) was tested. However, not only was the reducing agent ineffective, it was
found to inhibit TS activity at higher concentrations (EC50 ~100 mM), suggesting cysteine oxi-
dation is probably not the cause of TS-inactivation. Thus, preservation of TS activity seemed to
be specific for dUMP.
To characterise the stabilisation of recombinant T. brucei TS by dUMP, clarified thyA- E. coli
lysate containing Tsf-TbDHFR-TS was diluted 100-fold into assay buffer containing 100 μM
CH2THF and pre-incubated for different times before initiation of the reaction by the addition
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of dUMP (Fig 2A). In the absence of dUMP following desalting, TS activity decayed rapidly
with only 1% residual activity remaining after 3 min. The data was fitted to a single exponential
decay yielding a rate constant of 1.46 ± 0.11 min-1, from which a half-life of inactivation (t½) of
28 ± 2 s can be derived (Fig 2A, inset). The half maximal concentration of dUMP required to
stabilise TS activity in the absence of CH2THF was 12.6 ± 2.5 μM (Fig 2B). Over longer incuba-
tion times the addition of 200 μM dUMPmarkedly increased the stability of the diluted enzyme
by 700-fold (t½ = 330 min), but failed to completely stabilise TS activity (Fig 2A).
The stabilising effect of dUMP on Tsf-TbDHFR-TS was compared with LmDHFR-TS and
human TS expressed in thyA- E. coli as controls (Fig 2A). Both trypanosomatid enzymes were
found to be relatively unstable compared to the mono-functional human TS. Human TS
showed little or no activity loss over a five hour period in either the presence or absence of
dUMP. In contrast, LmDHFR-TS behaved more like TbDHFR-TS, but was ~20-fold more sta-
ble than TbDHFR-TS (t½ = 9.7 min). TbDHFR-TS was ultimately only partially stabilised by
dUMP, as evidenced by the loss of 50% total activity over a five hour period, whereas
LmDHFR-TS was effectively stable in presence of dUMP.
To establish if instability of TbDHFR-TS was also the case with the native enzyme, DHFR
and TS activity in lysates of T. brucei and thyA- E. coli expressing Tsf-TbDHFR-TS were com-
pared (Table 2). Tsf-TbDHFR-TS in desalted lysates is considerably less stable at higher tem-
perature, hence, lysates were incubated at 37°C for 1 h prior to activity determination. Before
incubation, the ratio of DHFR- to TS-activity for Tsf-TbDHFR-TS was calculated to be 53:1.
Both DHFR and TS activities in the recombinant enzyme decreased drastically following incu-
bation. Once again, the addition of dUMP improved the stability of TS while DHFR activity
was unaffected. The ratio of DHFR:TS activity (5:1) of the native enzyme before incubation
was in good agreement with values previously reported for T. brucei gambiense and T. lewisi
lysates [35]. DHFR activity of the native DHFR-TS remained unchanged after incubation,
Fig 2. Stabilisation of recombinant T. brucei TS activity by substrate dUMP. A. Determination of TS stability relative to dUMP
concentration using Tsf-TbDHFR-TS from thyA- lysate. Tsf-TbDHFR-TS (circles), LmDHFR-TS (squares), human TS (triangles).
Incubation mixtures omitted either 200 μM dUMP (open symbols) or 100 μMCH2THF (closed symbols); post-incubation, addition of
the missing reagent was used to initiate reactions. The inset shows the loss of TS activity Tsf-TbDHFR-TS in absence of dUMP over a
shorter time scale. All activities were determined in triplicate spectrophotometrically using 100 μMCH2THF, as described in the
methods. B. Optimum concentration of dUMP required to stabilise the TS activity. Activity was determined by incubating the diluted
lysate for 10 min in assay buffer with varying concentrations of dUMP prior to initiation of the reaction with CH2THF and excess
(200 μM) dUMP.
doi:10.1371/journal.pntd.0004714.g002
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while the decrease in TS activity was comparably less drastic compared to the recombinant
enzyme. The addition of dUMP to T. brucei lysates, however, did not protect against loss of TS
activity. These results suggest that the T. brucei endogenous TbDHFR-TS does not suffer the
same inactivation as the recombinant enzyme. In the event that a hitherto unknown TS activat-
ing factor might be present in T. brucei lysate, native and recombinant clarified lysates were
combined in a 1:1 ratio; this however resulted in no appreciable improvement in stability.
Purification of recombinant TbDHFR-TS
Having established the importance of dUMP in stabilising recombinant TbDHFR-TS, it was
subsequently included in all buffers used for the purification of Tsf-TbDHFR-TS and its TEV-
cleaved counterpart. Despite the presence of dUMP, TS activity was still completely lost during
purification regardless of whether TEV cleavage occurred at the start or end of the procedure.
Cleavage of Tsf-TbDHFR-TS prior to purification was only possible when glycerol was added
as a stabiliser to prevent rapid protein precipitation. Cleaved TbDHFR-TS was then purified by
methotrexate agarose affinity chromatography to near homogeneity in ~10% yield, along with
some residual un-cleaved Tsf-TbDHFR-TS (Fig 3A). The specific activity for the purified
enzyme was 24.3 U mg-1 for DHFR, with no detectable TS activity. The cleaved protein
behaved as a homodimer on size exclusion chromatography (Fig 3B) and sequence identity
confirmed by mass spectrometry fingerprinting with>70% sequence coverage, including the
C-terminal amino acid shown to be crucial for TS activity [36]. MALDI-TOF determination of
the exact total mass was not possible due to difficulties associated with desorption, although
low-resolution data also confirmed the presence of dimeric TbDHFR-TS.
In comparison, affinity chromatography of the un-cleaved Tsf-tagged TbDHFR-TS resulted in
a ~7-fold greater yield, suggesting Tsf significantly improved the stability of this enzyme. Follow-
ing elution from the methotrexate column, some minor contaminating proteins were visible by
SDS-PAGE; these were identified by mass spectrometry fingerprinting as Ef-Tu, the binding part-
ner of the Tsf tag, and E. coli hsp90. The latter could be removed by washing the column with
ATP prior to elution with methotrexate. In contrast, the control protein (LmDHFR-TS) could be
purified to homogeneity with retention of TS activity (DHFR 21.2 U mg-1; TS 0.89 Umg-1).
Kinetic characterisation of DHFR and TS activities
Purified Tsf-TbDHFR-TS was subsequently used for the kinetic characterisation of DHFR
domain and clarified crude lysates for the TS domain (S2 Fig). Using the spectrophotometric
Table 2. Stability of recombinant and native TbDHFR-TS in presence or absence of dUMP in bacterial or trypanosomal lysates.
Sample DHFR, mU mg-1 Residual activity, % TS mU mg-1 Residual activity, % Ratio DHFR:TS
Tsf-TbDHFR-TS control 1960 ± 168 100 37.3 ± 4.2 100 53
Tsf-TbDHFR-TS, 0.2 mM dUMP 487 ± 65 25 6.30 ± 0.67 17 77
Tsf-TbDHFR-TS, without dUMP 490 ± 30 25 1.66 ± 0.21 4 294
Native enzyme control 4.6 ± 0.8 100 0.95 ± 0.05 100 5
Native enzyme, 0.2 mM dUMP 4.2 ± 0.3 91 0.47 ± 0.05 49 9
Native enzyme, without dUMP 3.4 ± 0.3 74 0.47 ± 0.08 49 7
All samples were desalted and either supplemented to 0.2 mM dUMP or corrected for dilution effect with an equivalent volume of assay buffer prior to
incubation at 37°C for 1 h. DHFR activity was determined spectrophotometrically under saturating substrate concentrations and TS by radiometric assay
using 2.5 mM CH2THF and (saturating) 0.2 mM [3H]-dUMP, as described in the methods section. Control values are activities before incubation. Values
are the means and standard deviations of triplicate assays from a single experiment.
doi:10.1371/journal.pntd.0004714.t002
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assay, DHFR displayed a classical bell-shaped pH-optimum profile, with an optimal pH of ~5.5
(S2A Fig). In contrast, TS had a pH optimum of 7.0. The optimal ionic strength for both enzymes
required 100 mM KCl, with DHFR displaying 2.5-fold activation and TS 4.5-fold activation (S2B
Fig). This is consistent with previously reported KCl-dependent activation of this enzyme,
although our pH optimum profiles disagree [13]. TS could also be activated 4.5-fold with 10 mM
MgCl2 (30 mM ionic strength) and this effect was not additive with activation by KCl. Higher
concentrations of MgCl2 were inhibitory to TS, consistent with a previous report [37].
Since the intracellular pH of T. brucei has been reported to be 7.4 [38], a standardised assay
buffer consisting of 50 mMHEPES, pH 7.4 and 100 mM KCl was used for all subsequent stud-
ies. Under these conditions, Tsf-TbDHFR-TS obeys simple Michaelis-Menten kinetics with all
four substrates (Fig 4). The Km
app of Tsf-TbDHFR-TS and Tsf-cleaved TbDHFR-TS for DHF
were identical (4.1 ± 0.6 μM for Tsf-TbDHFR-TS and 4.2 ± 0.5 μM for the cleaved enzyme)
demonstrating that the tag did not interfere with the enzyme activity. The catalytic efficiency
for reduction of DHF was 6.8 x 106 M-1 s-1 consistent with DHFR from other organisms
(Table 3). Active site titration with methotrexate confirmed DHFR activity corresponding to
one site per monomer. Folic acid and the structurally related pterins (biopterin, dihydrobiop-
terin, sepiapterin and neopterin) were inactive as substrates for T. brucei DHFR (<17,000-fold
and<2,300-fold compared to DHF as substrate for folate and pterins, respectively). The inabil-
ity of TbDHFR-TS to reduce folate is in agreement with the L.major enzyme [39]; folate is pre-
sumed to be reduced to DHF by PTR1 (Fig 1).
The Km
app for dUMP (8.2 ± 0.6 μM) is in good agreement with TS from other organisms
and is consistent with the half maximal concentration of dUMP (12.6 ± 2.5 μM) required for
stability of TS. In contrast, the Km
app values for CH2THF were considerably more variable
between TS from various organisms. The affinity of the T. brucei enzyme was more similar to
that from the more distantly related C. fasciculata [37,41] (Table 3). The catalytic efficiency
Fig 3. Purification of recombinant Tsf-TbDHFR-TS from E. coli. A. SDS-PAGE gel stained with Coomassie blue. Lane 1. Clarified thyA- E.
coli lysate expressing Tsf-TbDHFR-TS. Lane 2. Glycerol-diluted lysate treated with TEV protease. Lane 3. Methotrexate agarose elution.
Proteins indicated by arrows identified by mass spectrometry to be Tsf-TbDHFR-TS, cleaved TbDHFR-TS, and the Tsf tag. B. Size exclusion
chromatography of purified product. Closed circles: DHFR activity. Dashed line: absorbance at 280 nm.
doi:10.1371/journal.pntd.0004714.g003
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(1.5 x 103 M-1 s-1) was considerably lower compared to those reported for recombinant T. cruzi
[29] and L.major [44] enzymes. These discrepancies could be due to the inherent instability of
the T. brucei enzyme or due to competing metabolism of CH2THF by other enzymes in the
crude thyA- E. coli lysate
In vitro effects of known DHFR and TS inhibitors on TbDHFR-TS
Known inhibitors of DHFR and TS from other organisms were tested for their potencies
against recombinant Tsf-TbDHFR-TS (Table 4). The greatest degree of TS inhibition was seen
with 5-fluorodeoxyuridine monophosphate (FdUMP), a dUMP-competitive TS-specific inhib-
itor which displayed tight-binding inhibition. The most potent DHFR inhibitors were the clas-
sic antifolate methotrexate and the trimethoxy-substituted trimetrexate. These compounds
were found to be tight-binding inhibitors with picomolar Ki values, while other antifolates
Fig 4. Kinetic constants for recombinant Tsf-TbDHFR-TS. (A) and (B) Determination of DHFR Kmapp values for DHF (4.1 ± 0.6 mM) and
NADPH (1.7 ± 0.2 mM), respectively, using purified enzyme. (C) and (D) Determination of TS Km
app values for dUMP (8.2 ± 0.6 mM) and
CH2THF (470 ± 50 mM), respectively, using clarified E. coli lysates. Assays were performed as described in methods. Values represent
weighted means of three independent determinations. One representative determination is shown for each Km
app.
doi:10.1371/journal.pntd.0004714.g004
Properties of Trypanosoma brucei Dihydrofolate Reductase-Thymidylate Synthase
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004714 May 13, 2016 12 / 20




















T. brucei 26 ± 1a 4.1 ± 0.6 1.7 ± 0.2 6.8 × 106 16 × 106 0.7± 0.1a 470± 50 8.2± 0.6 1.5 × 103 85 × 103
T. cruzi b 72 17 1.2 4.2 × 106 60 × 106 3.4 58 1.0 59 × 103 3,400 × 103
L. major c 27 1.3 0.7 21 × 106 38 × 106 0.44 51 6.0 8.6 × 103 73 × 103
Crithidia
fasciculata d
12 <2 6.7 6.0 × 106 1.8 × 106 1.4 400 3.3 3.5 × 103 420 × 103
Plasmodium
falciparum e
33 2.4 5.5 14 × 106 2.5 × 106 3.0 75 7.9 40 × 103 380 × 103
hDHFR f, hTS g,h 7.5 2.8 9.1 2.7 × 106 0.82 × 106 0.6 30 1.8 20 × 103 330 × 103
Spectrophotometric assays were used, apart from the determination of Km
app for CH2THF which required radiometric assay.
a) Value reported for TbDHFR-TS with Tsf tag removed. Tagged Tsf-TbDHFR-TS kcat 17 ± 1 s
-1. The kcat for TS is estimated based on DHFR
concentration in parasite lysate, assuming TS full site reactivity.
b) Reche et al. [29];
c) Meek et al. [40];
d) Ferone and Roland [41];
e) Prapunwattana et al. [42];
f) White et al. [43];
g). Dolnick and Cheng [32]
h) Reported value is Km
doi:10.1371/journal.pntd.0004714.t003
Table 4. Sensitivity of recombinant TbDHFR-TS to DHFR and TS inhibitors compared with their human counterparts.
Inhibitor DHFR Ki, nM TS Ki, nM
T. brucei Human T. brucei Human
Methotrexate 0.095 ± 0.006 0.0034a 46,300 ± 4,800 13,000g
Trimetrexate 0.597 ± 0.029 0.040b Inactive * —
Pyrimethamine 6.35 ± 0.49 1.2c 120d Inactive** —
Trimethoprim 17.6 ± 1.5 200c 1400d Inactive** —
Raltitrexed 93.1 ± 7.9 93e 215 ± 18 60e
Pemetrexed 290 ± 20 7.0f 20,500 ± 200 110f
Nolatrexed 348 ± 30 Inactiveh 39.4 ± 4.9 15h
FdUMP Inactive** Not reported 13.8 ± 1.3 1.7i
Ki values were determined using spectrophotometric methods. Values represent weighted mean and standard error of three independent determinations.
Human data from:
a Appleman et al. [45];
b Jackson et al. [46];
c Margosiak et al. [47];
d Chowdhury et al. [48];
e Jackman et al.[12];
f Shih et al. [11];
g Allegra et al. [49];
h Webber et al. [10];
i Dolnick and Cheng [32]
Inactive:
* No inhibition at 25 μM;
** No inhibition at 100 μM
doi:10.1371/journal.pntd.0004714.t004
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exhibited linear competitive inhibition with respect to the substrate, DHF. The diaminopyrimi-
dine antifolates trimethoprim and pyrimethamine were found to specifically inhibit DHFR, as
did the diaminoquinazoline trimetrexate. Trimethoprim, pyrimethamine and raltitrexed were
found to behave as potent competitive inhibitors of DHFR with Ki values of 11.4 ± 1.2,
17.6 ± 2.3 and 70.4 ± 7.2 nM, respectively, (Fig 5). These values are in good agreement with
those determined using the IC50 method in Table 4. Other antifolates possessed varying degrees
of both DHFR and TS inhibition. Apart from the TS substrate analogue FdUMP, the only
inhibitor that possessed greater inhibition of TS than DHFR as tested was nolatrexed, showing
10-fold TS selectivity. Chemical structures of the inhibitors are shown in Fig 6.
In vivo effects of known DHFR and TS inhibitors on T. brucei
Antifolate drugs had highest potency against bloodstream forms of T. brucei when tested in a
medium deficient in folate and thymidine, with the exception of the lipophilic drug nolatrexed
where potency did not change between media types (Table 5). Indeed methotrexate, peme-
trexed and raltitrexed possess nanomolar potency in a thymidine and folate deficient media.
The addition of folate and thymidine reduced the potencies of the antifolates, except nola-
trexed. For methotrexate, pyrimethamine and trimethoprim the addition of folate had a greater
effect in reducing potency than the addition of thymidine. For raltitrexed and pemetrexed the
Fig 5. Modality of inhibition of antifolate drugs against DHFR activity. (A) pyrimethamine, (B) trimethoprim and (C) raltitrexed.
Recombinant TbDHFR-TS was assayed in the presence of varying concentrations of substrate (DHF) and fixed amounts of inhibitor (see
legends for concentrations in nM). Each double reciprocal plot was inspected for inhibition pattern and then globally fitted by non-linear
regression to equations describing either competitive or mixed inhibition. Statistical F-tests using GraFit revealed that competitive
inhibition gave the best fit in all cases.
doi:10.1371/journal.pntd.0004714.g005
Fig 6. Chemical structures of DHFR and TS inhibitors.
doi:10.1371/journal.pntd.0004714.g006
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addition of thymidine had a greater effect in reducing drug potency than the addition of folate.
For the lipophilic inhibitor trimetrexate the addition of folate or the addition of thymidine had
a comparable effect on reducing drug potency.
Discussion
The TS activity of recombinant TbDHFR-TS is highly unstable (t½ 28 s) compared to other
organisms, with the T. brucei enzyme proving to be the least stable TS yet reported. Addition of
dUMP increases enzyme stability, as in other organisms, but proved insufficient to achieve
purification of active enzyme. Other stabilising agents, including mercaptoethanol, did not pre-
vent inactivation, unlike human TS that can be stored at 4°C for 3 months without loss of activ-
ity [50]. This remarkable instability could account for the inefficient complementation and
slow growth of TS-deficient E. coli expressing TbDHFR-TS. However, the basis for instability is
not known. A previous report suggested that sequential degradations at the C-terminus
together with internal cleavage in the TS domain may be responsible [13]. Our purified recom-
binant protein showed no evidence of proteolytic cleavage by either SDS-PAGE or MALDI--
TOF MS and the C-terminus of TS was identified by MS fingerprinting, including the final
residue required for catalysis. Thus, proteolysis can be discounted, as can oxidation of the cata-
lytic cysteine since thiols did not stabilise the protein. Other possible stabilising agents include
parasite-specific interacting macromolecules (e.g. mRNA or protein chaperones), or parasite-
specific post-translational modifications. Further research is required to test these possibilities.
A variety of DHFR and TS inhibitors were examined using bifunctional recombinant
TbDHFR-TS, all of which, apart from FdUMP, can be categorised as antifolates. Overall, T.
brucei DHFR appears to be more exploitable in terms of selective inhibition over the human
homologue than TS.
In the current study, the only molecules to possess picomolar Ki values against DHFR were
trimetrexate and methotrexate, consistent with a previous report [51]. Maximal methotrexate
potency in vivo was found to be dependent on the absence of thymidine from T. brucei growth
media, thus confirming that thymineless death is part of its mode of action. However, the
inability of thymidine to completely reverse methotrexate toxicity suggests that additional tar-
gets also exist beyond DHFR and TS. One likely candidate is pteridine reductase 1 (Ki
app 11.1
nM) [51], another validated target in these parasites [52,53]. Compared to methotrexate, the
pronounced potency of trimetrexate against DHFR is not reflected against whole cells likely
due to the fact that trimetrexate is lipophilic and lacks a terminal glutamyl moiety for polyglu-
tamylation and increased retention in the trypanosome (Fig 6).
Table 5. Effect of folate and thymidine on sensitivity of T. brucei to DHFR-TS inhibitors in vitro.
Inhibitor No addition + Thymidine + Folate + Thymidine + Folate
Methotrexate 0.012 ± 0.001 0.12 ± 0.03 1.31 ± 0.13 8.16 ± 2.78
Trimetrexate 0.32 ± 0.02 2.82 ± 0.36 1.23 ± 0.06 4.09 ± 0.35
Pyrimethamine 2.26 ± 0.32 2.01 ± 0.34 6.32 ± 0.71 6.87 ± 0.33
Trimethoprim 48.8 ± 3.7 59.8 ± 8.6 170 ± 28 145 ± 22
Raltitrexed 0.038 ± 0.001 > 250 64.8 ± 4.3 > 250
Pemetrexed 0.020 ± 0.001 > 250 12.9 ± 1.1 >250
Nolatrexed 33.8 ± 3.7 32.7 ± 4.7 21.8 ± 2.0 39.6 ± 7.2
Cells were cultured in TBM with the addition of thymidine (160 μM) and/or folate (9 μM) as described in Experimental section. Units for EC50 values
are μM. Results are the weighted means ± standard error of 3 independent experiments
doi:10.1371/journal.pntd.0004714.t005
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Trimethoprim and pyrimethamine are both competitive inhibitors with intermediate potency
against T. bruceiDHFR. Our Ki values are 30- to 60-fold higher than first reported [13], but con-
sistent with a subsequent report [48]. For these diaminopyrimidines, this translates to modest
selectivity at best between parasite and host DHFR, compared to the> 100,000-fold selectivity
of the antibacterial trimethoprim between human and E. coliDHFR [54]. A variety of novel dia-
minopyrimidines reported by Chowdhury et al. have been shown to be potent against T. brucei
DHFR with nanomolar Ki values and selectivity up to 610-fold over the human enzyme [48].
However, toxicity and poor in vivo potency were limitations associated with these compounds.
Both trimethoprim and pyrimethamine displayed a marked drop-off in potency from target to
cell, when cultured in a medium deficient in thymidine and folate. Like trimetrexate these are
lipophilic antifolates and do not contain a terminal glutamyl moiety. The addition of thymidine
had little impact on cell potency of pyrimethamine or trimethoprim, implying that thymineless
death is not their sole mode of action. This is consistent with a previous report which showed
that the potency of pyrimethamine was not significantly affected by knocking out dhfr-ts [6].
With regards to antifolates possessing selectivity for TS over DHFR, compounds with a pri-
mary amine at position 4 correlated with stronger inhibition of DHFR, as was expected from
previous reports, whereas a carbonyl substituent in this position is known to favour TS inhibi-
tion by means of additional hydrogen bonding provided by the oxygen atom [55]. TS-targeted
antifolates also frequently include a terminal glutamyl moiety which is polyglutamylated in
vivo by the enzyme folylpolyglutamyl synthetase (FPGS) [56]. This results in tighter binding to
TS, with little effect on DHFR, and improved cellular retention. Although a candidate gene for
FPGS is present in the T. brucei genome [57], it has not yet been studied in this species; how-
ever, in the related trypanosome Leishmania, intracellular folates possess on average 3–5 gluta-
mates [58], thus this is likely also the case in T. brucei. Of the TS-targeted antifolates tested, the
only compound which cannot exploit polyglutamylation was nolatrexed. Without the need for
polyglutamylation, nolatrexed was found to be 10-fold TS selective; however, in vivo data
showed moderate whole cell potencies. By comparison, the monoglutamate forms of raltitrexed
and pemetrexed, generally thought of as TS-targeted antifolates in their polyglutamate forms,
were found to be more potent against DHFR than TS, as has previously been observed with the
monofunctional human enzymes [11,12]. Raltitrexed and pemetrexed are more potent against
whole parasites than they are against DHFR or TS suggesting that polyglutamylation is likely
to occur inside T. brucei. Off-target effects can be discounted since the trypanocidal action of
these drugs is completely abrogated by thymidine and suggests that these inhibitors are likely
to be TS-specific in vivo. Further work is required to substantiate this hypothesis.
Based on our observations regarding the inhibition of DHFR and TS by known antifolates,
and their potency in vivo with regards to thymidine bypass, it is clear that additional targets
must exist in T. brucei. Given their structural similarity to folate metabolites, possible alterna-
tive targets would be the FPGS, the glycine cleavage system, methionine synthase (Fig 1) or the
bifunctional N5,N10-methylenetetrahydrofolate dehydrogenase-N5,N10-methenyltetrahydrofo-
late cyclohydrolase (DHCH). If the inhibition of one or more of these proposed targets can be
identified then they could potentially be explored as alternative targets for the disruption of
folate metabolism, which could be of interest for future drug discovery should TbDHFR-TS
prove difficult to exploit.
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